# An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

> **NCT01646827** · PHASE1 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 37 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole IM Depot

## Key facts

- **NCT ID:** NCT01646827
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2014-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01646827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01646827, "An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01646827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*